Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

The drugmaker has cutting even in frontline production roles as it looks to streamline costs and reposition itself in the heated weight-loss drug market.

According to a Reuters review of LinkedIn posts, affected staff in quality control, production, and other technical roles at the Clayton facility, which produces semaglutide, the active ingredient in obesity drug Wegovy and diabetes treatment Ozempic.

Also Read: Novo Nordisk’s Wegovy Outperforms Eli Lilly’s Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

While relatively small compared with the company’s planned 9,000 global ...